LumiraDx jumps on approval for COVID-19 antigen test in India

LumiraDx

20/10/2021 14:25

** Diagnostic testing co shares  LMDX  rise as much as 78%
to $15.01, among top pct gainers before the bell  
    ** LMDX receives emergency use approval from India's Central
Drugs Standard Control Organisation for its SARS-CoV-2 Antigen
test  Pn2gv7z4a 
    ** Co's antigen test kit, which returns results in under 12
mins, includes a testing strip and a small, portable instrument
for running results 
    ** Co's COVID-19 antigen Test is currently available in
about 30 countries worldwide, including the United States,
Japan, Brazil as well as in Europe 
    ** Last month, LMDX closed business combination with SPAC CA
Healthcare Acquisition Corp  Bwc07Th4a  
    ** As of Tuesday's close, LMDX up ~6% since its Sept 29
debut on Nasdaq 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))